LIDIA TIMOFEENKO PETERSEN: Open Payments
NPI 1245857952 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,857 in 91 payments from 9 companies in 2025. Trend: 2023 $1,182 · 2024 $1,831 · 2025 $2,857
Food & beverage: $2,045Consulting: $812
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $933 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $452 |
| Neurocrine BioSciences, Inc. | 17 | $433 |
| Alkermes, Inc. | 14 | $301 |
| E.R. Squibb & Sons, L.L.C. | 14 | $279 |
| Teva Pharmaceuticals USA, Inc. | 11 | $170 |
| ABBVIE INC. | 7 | $145 |
| Janssen Pharmaceuticals, Inc | 7 | $122 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
Products named: ABILIFY MAINTENA, CAPLYTA, INGREZZA, ARISTADA, COBENFY, VRAYLAR, INVEGA SUSTENNA, REXULTI.
Industry payments across NV — which companies pay providers there.
